11:17 AM EDT, 03/12/2024 (MT Newswires) -- European equities traded in the US as American depositary receipts were trending moderately higher Tuesday morning rising 0.65% to 1,367.36 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company Cellectis ( CLLS ) and pharmaceutical company Ascendis Pharma ( ASND ) , which rose 8.2% and 3.6% respectively. They were followed by biopharmaceutical company DBV Technologies ( DBVT ) and financial services company ING (ING), which increased 2.8% and 2.4% respectively.

The decliners from continental Europe were led by biopharmaceutical companies Grifols ( GRFS ) and Calliditas Therapeutics ( CALT ) , which lost 3.8% and 3.1% respectively. They were followed by biotech firms Evaxion Biotech ( EVAX ) and Biophytis ( BPTS ) , which were down 1.9% and 1.1% respectively.

From the UK and Ireland, the gainers were led by pharmaceutical company Silence Therapeutics ( SLN ) and biopharmaceutical company TC Biopharm ( TCBP ) , which rose 4.1% and 3% respectively. They were followed by insurance firm Prudential (PUK) and financial services company HSBC ( HSBC ) , which were up 2.9% and 2.3% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Amarin ( AMRN ) and Adaptimmune Therapeutics ( ADAP ) , which dropped 3.9% and 3.2% respectively. They were followed by biopharmaceutical company Biodexa Pharmaceuticals ( BDRX ) and biotech firm Autolus Therapeutics ( AUTL ) , which fell 2% and 1.7% respectively.